Abstract
The present application relates to a bi-functional therapeutic for treating cancer that includes a targeting component which targets a tumor-associated antigen and an enzyme which, when delivered to a tumor by said targeting component, converts the tumor phenotype to that of an incompatible allograft or xenograft. The enzyme is coupled to the targeting component. Also disclosed is a method for treating cancer comprising administering the bi-functional therapeutic.
Full Text
What is claimed is:
The present application relates to a bi-functional therapeutic for treating cancer that includes a targeting component which targets a tumor-associated antigen and an enzyme which, when delivered to a tumor by said targeting component, converts the tumor phenotype to that of an incompatible allograft or xenograft. The enzyme is coupled to the targeting component. Also disclosed is a method for treating cancer comprising administering the bi-functional therapeutic.
Timeline
Filed
03/13/2026Published
07/02/2026Granted
Not AvailableIPC Codes(6)
A61K 47/66:the modifying agent being a pre-targeting system involving a peptide or protein for targeting specific cells
A61K 39/00:Medicinal preparations containing antigens or antibodies (materials for immunoassay G01N 33/53)
A61P 35/00:Antineoplastic agents